COMPANY
ImmuneSensor Therapeutics
Timeline
- Trial start 1: Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies source ↗
- Trial start Phase 1: A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial source ↗
- Trial start Phase 2: Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies source ↗
- Trial start Phase 2: Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy Study of IMSA101 in Refractory Malignancies source ↗
Clinical trials (lead sponsor) 5
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05846659 | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | Phase 2 | Terminated | Jul 7, 2023 | Nov 20, 2024 (actual) |
| NCT07364513 | Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies | 1 | Recruiting | Jan 12, 2026 | Jul 30, 2026 (estimated) |
| NCT05846646 | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | Phase 2 | Terminated | Jun 28, 2023 | Sep 16, 2024 (actual) |
| NCT04020185 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Phase 1/Phase 2 | Completed | Sep 23, 2019 | Sep 15, 2023 (actual) |
| NCT06026254 | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | Phase 1 | Active, not recruiting | Sep 15, 2023 | 2025-09 (estimated) |